Browsing by Author "Rovira Guerín, Ana"

Sort by: Order: Results:

  • Rincón, Raúl; Cristóbal, Ion; Zazo, Sandra; Arpí Llucià, Oriol; Menendez Romero, Silvia; Manso, Rebeca; Lluch, Ana; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; García-Foncillas, Jesús; Madoz-Gúrpide, Juan; Rojo, Federico (Impact Journals, 2015)
    The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A ...
  • Hardy-Werbin, Max; Rocha, Pedro P.; Arpí Llucià, Oriol; Taus García, Álvaro; Nonell Mazelon, Lara, 1972-; Duran Jordà, Xavier, 1974-; Villanueva, Xavier; Joseph-Pietras, Debora; Nolan, Luke; Danson, Sarah; Griffiths, Richard; López-Botet, M. (Miguel); Rovira Guerín, Ana; Albanell Mestres, Joan; Ottensmeier, Christian; Arriola Aperribay, Edurne (Taylor & Francis, 2019)
    Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory ...
  • Luque, Melani; Sanz Álvarez, Marta; Santamaría, Andrea; Zazo, Sandra; Cristóbal, Ion; Fuente, Lorena de la; Mínguez, Pablo; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; Rojo, Federico (MDPI, 2021)
    The combination of trastuzumab plus pertuzumab plus docetaxel as a first-line therapy in patients with HER2-positive metastatic breast cancer has provided significant clinical benefits compared to trastuzumab plus docetaxel ...
  • Adam-Artigues, Anna; Rovira Guerín, Ana; Albanell Mestres, Joan; Arribas, Joaquín; Cejalvo, Juan M. (American Association for the Advancement of Science (AAAS), 2022)
    Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of ...
  • Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstman, Rodrigo; González-Pérez, Abel; López Bigas, Núria (Universitat Pompeu Fabra, 2016-10)
    CGI drug prescription assigns targeted drugs to a tumor, based on its genomic alterations, according different levels of evidence (from pre-clinical assays to clinical guidelines).
  • Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...
  • González-Alonso, Paula; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico (MDPI, 2020)
    Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the ...
  • Tormo, Eduardo; Ballester, Sandra; Adam-Artigues, Anna; Burgués, Octavio; Alonso, Elisa; Bermejo, Begoña; Menendez Romero, Silvia; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Research, 2019)
    The mechanisms of chemotherapy resistance in triple negative breast cancer remain unclear, and so, new molecules which might mediate this resistance could optimize treatment response. Here we analyzed the involvement of ...
  • Tormo, Eduardo; Adam-Artigues, Anna; Ballester, Sandra; Pineda, Begoña; Zazo, Sandra; González-Alonso, Paula; Albanell Mestres, Joan; Rovira Guerín, Ana; Rojo, Federico; Lluch, Ana; Eroles, Pilar (Nature Publishing Group, 2017)
    A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking